反应详情

Following the procedure described for compound N-(6-(6-chloro-5-(4-(2-hydroxypropan-2-yl)phenylsulfonamido)pyridin-3-yl)imidazo[1,2-b]pyridazin-2-yl)acetamide (Example 35), N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-b]pyridazin-2-yl)acetamide (200 mg, 662 μmol) (Example 35, Step 3) was reacted with N-(5-bromo-2-chloropyridin-3-yl)-2-chloro-4-fluorobenzenesulfonamide (265 mg, 662 μmol) to afford the title compound as a grey solid (50 mg, 25% yield). MS (ESI positive ion) m/z: 495 (M+1). 1H NMR (400 MHz, DMSO-d6): δ ppm 2.12 (s, 3H), 7.33-7.43 (m, 1H), 7.77 (dd, J=8.61, 2.15 Hz, 1H), 7.83 (d, J=9.39 Hz, 1H), 7.99 (dd, J=8.80, 6.06 Hz, 1H), 7.99 (dd, J=8.80, 6.06 Hz, 1H), 8.12 (d, J=9.39 Hz, 1H), 8.33 (d, J=8.41 Hz, 2H), 8.91 (s, 1H), 10.82-10.92 (br s, 1H), 10.96 (s, 1H).